Fasting pancreatic polypeptide predicts incident microvascular and macrovascular complications of type 2 diabetes: An observational study.
diabetes mellitus
diabetic retinopathy
microvascular disease
pancreatic polypeptide
visceral adiposity
Journal
Diabetes/metabolism research and reviews
ISSN: 1520-7560
Titre abrégé: Diabetes Metab Res Rev
Pays: England
ID NLM: 100883450
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
revised:
26
04
2024
received:
05
10
2023
accepted:
21
05
2024
medline:
8
6
2024
pubmed:
8
6
2024
entrez:
8
6
2024
Statut:
ppublish
Résumé
Pancreatic polypeptide (PP) is elevated in people with vascular risk factors such as type 2 diabetes or increased visceral fat. We investigated potential relationships between PP and microvascular and macrovascular complications of diabetes. Animal study: Subcutaneous PP infusion for 4 weeks in high fat diet mouse model. Retinal mRNA submitted for Ingenuity Pathway Analysis. Human study: fasting PP measured in 1478 participants and vascular complications recorded over median 5.5 (IQR 4.9-5.8) years follow-up. Animal study: The retinal transcriptional response to PP was indicative of cellular stress and damage, and this footprint matched responses described in previously published studies of retinal disease. Of mechanistic importance the transcriptional landscape was consistent with upregulation of folliculin, a recently identified susceptibility gene for diabetic retinopathy. Human study: Adjusting for established risk factors, PP was associated with prevalent and incident clinically significant retinopathy (odds ratio (OR) 1.289 (1.107-1.501) p = 0.001; hazard ratio (HR) 1.259 (1.035-1.531) p = 0.0213), albuminuria (OR 1.277 (1.124-1.454), p = 0.0002; HR 1.608 (1.208-2.141) p = 0.0011), and macrovascular disease (OR 1.021 (1.006-1.037) p = 0.0068; HR 1.324 (1.089-1.61), p = 0.0049), in individuals with type 2 diabetes, and progression to diabetes in non-diabetic individuals (HR 1.402 (1.081-1.818), p = 0.0109). Elevated fasting PP is independently associated with vascular complications of diabetes and affects retinal pathways potentially influencing retinal neuronal survival. Our results suggest possible new roles for PP-fold peptides in the pathophysiology of diabetes complications and vascular risk stratification.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3829Subventions
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Diabetes UK
Pays : United Kingdom
Organisme : National Institute for Health and Care Research
Organisme : Biotechnology and Biological Sciences Research Council
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Mubadala
Organisme : Imperial College Healthcare NHS Trust
Organisme : Imperial College London
Informations de copyright
© 2024 The Author(s). Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.
Références
Boussageon R, Bejan‐Angoulvant T, Saadatian‐Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta‐analysis of randomised controlled trials. Br Med J Abstr. 2011;343(jul26 1):d4169. https://doi.org/10.1136/bmj.d4169
Chew EY, Davis MD, Danis RP, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014;121(12):2443‐2451. https://doi.org/10.1016/j.ophtha.2014.07.019
Saputro SA, Pattanaprateep O, Pattanateepapon A, Karmacharya S, Thakkinstian A. Prognostic models of diabetic microvascular complications: a systematic review and meta‐analysis. Syst Rev. 2021;10(1):288. https://doi.org/10.1186/s13643‐021‐01841‐z
Zhong P, Tan S, Zhu Z, et al. Normal‐weight central obesity and risk of cardiovascular and microvascular events in adults with prediabetes or diabetes: Chinese and British cohorts. Diabetes Metab Res Rev. 2023;39(8):e3707. https://doi.org/10.1002/dmrr.3707
Anan F, Masaki T, Ito Y, et al. Diabetic retinopathy is associated with visceral fat accumulation in Japanese type 2 diabetes mellitus patients. Metabolism. 2010;59(3):314‐319. https://doi.org/10.1016/j.metabol.2009.06.001
Coutinho T, Goel K, Corrêa de Sá D, et al. Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. J Am Coll Cardiol. 2011;57(19):1877‐1886. https://doi.org/10.1016/j.jacc.2010.11.058
Tallam H, Elton DC, Lee S, Wakim P, Pickhardt PJ, Summers RM. Fully automated abdominal CT biomarkers for type 2 diabetes using deep learning. Radiology. 2022;304(1):85‐95. https://doi.org/10.1148/radiol.211914
Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;106(36):15430‐15435. https://doi.org/10.1073/pnas.0904944106
Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020;126(11):1477‐1500. https://doi.org/10.1161/circresaha.120.316101
Sam AH, Sleeth ML, Thomas EL, et al. Circulating pancreatic polypeptide concentrations predict visceral and liver fat content. J Clin Endocrinol metabolism. 2015;100(3):1048‐1052. https://doi.org/10.1210/jc.2014‐3450
Aerts E, Beckers S, Zegers D, et al. CNV analysis and mutation screening indicate an important role for the NPY4R gene in human obesity. Obesity. 2016;24(4):970‐976. https://doi.org/10.1002/oby.21435
Shebanits K, Andersson‐Assarsson JC, Larsson I, Carlsson LMS, Feuk L, Larhammar D. Copy number of pancreatic polypeptide receptor gene NPY4R correlates with body mass index and waist circumference. PLoS One. 2018;13(4):e0194668. https://doi.org/10.1371/journal.pone.0194668
Floyd JC, Fajans SS, Pek S, Chance RE. A newly recognized pancreatic polypeptide; plasma levels in health and disease. In: Proceedings of the 1976 Laurentian Hormone Conference. Elsevier; 1977:519‐570.
Tsuda K, Sakurai H, Seino Y, et al. Abnormal pancreatic polypeptide response to oral glucose loading diabetes mellitus. Clin Endocrinol. 1980;13(5):425‐429. https://doi.org/10.1111/j.1365‐2265.1980.tb03407.x
King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877‐894. https://doi.org/10.1111/j.1476‐5381.2012.01911.x
Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz PH. Proceedings: radioimmunoassay of a new gut hormone‐human pancreatic polypeptide. Gut. 1976;17:393‐394.
Thomas RL, Halim S, Gurudas S, Sivaprasad S, Owens DR. IDF Diabetes Atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes Res Clin Pract. 2019;157:107840. https://doi.org/10.1016/j.diabres.2019.107840
Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116(9):1509‐1526. https://doi.org/10.1161/circresaha.116.303849
Ribes G, Trimble ER, Wollheim CB, Blayac JP, Loubatieres‐Mariani MM. Stimulation of pancreatic polypeptide secretion in the dog by hypoglycemic agent HB 699. Am J Physiol. 1983;244:E380‐E384. https://doi.org/10.1152/ajpendo.1983.244.4.e380
Cuenco J, Minnion J, Tan T, et al. Degradation paradigm of the gut hormone, pancreatic polypeptide, by hepatic and renal peptidases. Endocrinology. 2017;158(6):1755‐1765. https://doi.org/10.1210/en.2016‐1827
Tanaka S, Iimuro S, Yamashita H, et al. Predicting macro‐ and microvascular complications in type 2 diabetes: the Japan diabetes complications study/the Japanese elderly diabetes intervention trial risk engine. Diabetes Care. 2013;36(5):1193‐1199. https://doi.org/10.2337/dc12‐0958
Rådholm K, Chalmers J, Ohkuma T, et al. Use of the waist‐to‐height ratio to predict cardiovascular risk in patients with diabetes: results from the ADVANCE‐ON study. Diabetes Obes Metab. 2018;20(8):1903‐1910. https://doi.org/10.1111/dom.13311
Wander PL, Boyko EJ, Leonetti DL, McNeely MJ, Kahn SE, Fujimoto WY. Change in visceral adiposity independently predicts a greater risk of developing type 2 diabetes over 10 Years in Japanese Americans. Diabetes Care. 2013;36:289‐293. https://doi.org/10.2337/dc12‐0198
Amato MC, Giordano C, Galia M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920‐922. https://doi.org/10.2337/dc09‐1825
Schwartz TW. Pancreatic polypeptide: a hormone under vagal control. Gastroenterology. 1983;85(6):1411‐1425. https://doi.org/10.1016/s0016‐5085(83)80027‐4
Miyato H, Kitayama J, Hidemura A, Ishigami H, Kaisaki S, Nagawa H. Vagus nerve preservation selectively restores visceral fat volume in patients with early gastric cancer who underwent gastrectomy. J Surg Res. 2012;173(1):60‐67. https://doi.org/10.1016/j.jss.2010.08.040
Asakawa A, Inui A, Yuzuriha H, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology. 2003;124(5):1325‐1336. https://doi.org/10.1016/s0016‐5085(03)00216‐6
Lam TKT, Pocai A, Gutierrez‐Juarez R, et al. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med. 2005;11(3):320‐327. https://doi.org/10.1038/nm1201
Bard JA, Walker MW, Branchek TA, Weinshank RL. Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J Biol Chem. 1995;270(45):26762‐26765. https://doi.org/10.1074/jbc.270.45.26762
Sheng W, Yu M, Wang X, et al. Localization of neuropeptide receptor NPY4R in rat retina. Neuropeptides. 2022;93:102246. https://doi.org/10.1016/j.npep.2022.102246
Bedoui S, Kromer A, Gebhardt T, et al. Neuropeptide Y receptor‐specifically modulates human neutrophil function. J Neuroimmunol. 2008;195(1‐2):88‐95. https://doi.org/10.1016/j.jneuroim.2008.01.012
Skol AD, Jung SC, Sokovic AM, et al. Integration of genomics and transcriptomics predicts diabetic retinopathy susceptibility genes. Elife. 2020;9:e59980. https://doi.org/10.7554/elife.59980
Hasumi H, Baba M, Hasumi Y, et al. Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN. J Natl Cancer Inst. 2012;104(22):1750‐1764. https://doi.org/10.1093/jnci/djs418
St‐Pierre J, Drori S, Uldry M, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC‐1 transcriptional coactivators. Cell. 2006;127(2):397‐408. https://doi.org/10.1016/j.cell.2006.09.024
Wu J, Ruas JL, Estall JL, et al. The unfolded protein response mediates adaptation to exercise in skeletal muscle through a PGC‐1α/ATF6α complex. Cell Metab. 2011;13(2):160‐169. https://doi.org/10.1016/j.cmet.2011.01.003
Possik E, Jalali Z, Nouët Y, et al. Folliculin regulates ampk‐dependent autophagy and metabolic stress survival. PLoS Genet. 2014;10(4):e1004273. https://doi.org/10.1371/journal.pgen.1004273
Chen Y, Sawada O, Kohno H, et al. Autophagy protects the retina from light‐induced degeneration. J Biol Chem. 2013;288(11):7506‐7518. https://doi.org/10.1074/jbc.m112.439935
Wang T, Lao U, Edgar BA. TOR‐mediated autophagy regulates cell death in Drosophila neurodegenerative disease. J Cell Biol. 2009;186(5):703‐711. https://doi.org/10.1083/jcb.200904090
Liu J, Copland DA, Theodoropoulou S, et al. Impairing autophagy in retinal pigment epithelium leads to inflammasome activation and enhanced macrophage‐mediated angiogenesis. Sci Rep. 2016;6(1):20639. https://doi.org/10.1038/srep20639
Yao J, Tao ZF, Li CP, et al. Regulation of autophagy by high glucose in human retinal pigment epithelium. Cell Physiol Biochem. 2014;33(1):107‐116. https://doi.org/10.1159/000356654